Most Recent
Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
Intellectual Property 2024-11-22 2:45 pm By Sam Matthews

As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

AstraZeneca sues to put the brakes on Brilinta generic
Intellectual Property 2024-10-29 11:33 pm By Andy Sidler

AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta. 

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Top cancer institute wins patent for patient-specific vaccine
Intellectual Property 2024-08-09 10:20 pm By Andy Sidler

US-based Dana-Farber Cancer Institute has succeeded in patenting a patient-specific method for developing cancer vaccines using genome sequencing.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Samsung Bioepis’ ‘scattergun approach’ dooms bid for R&D docs in fight over Pfizer’s Enbrel patent
Intellectual Property 2024-06-27 11:54 pm By Andy Sidler

A judge has rejected Samsung Bioepis’ bid to discover research and development documents from Pfizer as it seeks to invalidate the drug giant’s patent for its blockbuster autoimmune drug Enbrel, agreeing with Pfizer that it may be “no more than an exercise in fishing”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pfizer calls out ‘impermissible fishing expedition’ in fight over Enbrel biosimilar
Intellectual Property 2024-06-05 10:17 pm By Andy Sidler

Drug giant Pfizer has blasted Samsung Bioepis’ “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.  

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Vector Corrosion not entitled to concrete treatment patent, judge finds
Intellectual Property 2022-03-17 3:28 pm By Miklos Bolza

Concrete repair company Vector Corrosion Technologies has lost its bid for ownership of a concrete treatment patent held by three former employees who jumped ship, with a court finding the trio invented the technology after leaving Vector.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pfizer, Merck Sharpe & Dohme reach global settlement in vaccine patent battle
Intellectual Property 2021-09-24 6:25 pm By Cindy Cameronne

Pharmaceutical giants Merck Sharpe & Dohme and Pfizer have resolved a long-running intellectual property dispute over a 2015 patent owned by Pfizer for a pneumococcal vaccine.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Death causes six-month delay of trial in Merck, Pfizer vaccine patent dispute
Intellectual Property 2021-02-03 5:18 pm By Cat Fredenburgh

The Federal Court has delayed a 15-day hearing in a pneumococcal vaccine patent dispute between Merck Sharp & Dohme and Pfizer after the sudden death of a family member of one of Pfizer’s expert witnesses.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Merck Sharp & Dohme lodges cross appeal in Prevnar 13 vaccine patent spat
Intellectual Property 2021-01-25 4:33 pm By Christine Caulfield

Drug giant Merck Sharp & Dohme has brought a cross appeal in its long-running intellectual property dispute with Pfizer’s Wyeth over the top selling Prevnar 13 pneumococcal vaccine.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Wyeth seeks total victory in vaccine patent battle with Merck Sharp & Dohme
Intellectual Property 2021-01-15 8:53 am By Cat Fredenburgh

Pfizer unit Wyeth is seeking to overturn part of a judge’s decision in its high-stakes patent dispute with Merck Sharp & Dohme that found claims in two of its patents relating to the blockbuster Prevnar 13 pneumococcal vaccine were invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?